These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 28557974)
1. Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice. Martikainen M; Ruotsalainen J; Tuomela J; Härkönen P; Essand M; Heikkilä J; Hinkkanen A Br J Cancer; 2017 Jun; 117(1):51-55. PubMed ID: 28557974 [TBL] [Abstract][Full Text] [Related]
2. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma. Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Määttä AM; Liimatainen T; Wahlfors T; Wirth T; Vähä-Koskela M; Jansson L; Valonen P; Häkkinen K; Rautsi O; Pellinen R; Mäkinen K; Hakumäki J; Hinkkanen A; Wahlfors J Int J Cancer; 2007 Aug; 121(4):863-70. PubMed ID: 17443493 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma. Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187 [TBL] [Abstract][Full Text] [Related]
5. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Vähä-Koskela MJ; Kallio JP; Jansson LC; Heikkilä JE; Zakhartchenko VA; Kallajoki MA; Kähäri VM; Hinkkanen AE Cancer Res; 2006 Jul; 66(14):7185-94. PubMed ID: 16849565 [TBL] [Abstract][Full Text] [Related]
7. Interferon-β sensitivity of tumor cells correlates with poor response to VA7 virotherapy in mouse glioma models. Ruotsalainen J; Martikainen M; Niittykoski M; Huhtala T; Aaltonen T; Heikkilä J; Bell J; Vähä-Koskela M; Hinkkanen A Mol Ther; 2012 Aug; 20(8):1529-39. PubMed ID: 22434140 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense. Echchgadda I; Chang TH; Sabbah A; Bakri I; Ikeno Y; Hubbard GB; Chatterjee B; Bose S BMC Cancer; 2011 Jan; 11():43. PubMed ID: 21276246 [TBL] [Abstract][Full Text] [Related]
9. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133 [TBL] [Abstract][Full Text] [Related]
11. Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus. Ramachandran M; Yu D; Dyczynski M; Baskaran S; Zhang L; Lulla A; Lulla V; Saul S; Nelander S; Dimberg A; Merits A; Leja-Jarblad J; Essand M Clin Cancer Res; 2017 Mar; 23(6):1519-1530. PubMed ID: 27637889 [No Abstract] [Full Text] [Related]
12. Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer. Schenk E; Essand M; Kraaij R; Adamson R; Maitland NJ; Bangma CH Hum Gene Ther Clin Dev; 2014 Mar; 25(1):7-15. PubMed ID: 24649837 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Lee CY; Rennie PS; Jia WW Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871 [TBL] [Abstract][Full Text] [Related]
14. Potent oncolytic activity of human enteroviruses against human prostate cancer. Berry LJ; Au GG; Barry RD; Shafren DR Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643 [TBL] [Abstract][Full Text] [Related]
15. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740 [TBL] [Abstract][Full Text] [Related]
16. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Holl EK; Brown MC; Boczkowski D; McNamara MA; George DJ; Bigner DD; Gromeier M; Nair SK Oncotarget; 2016 Nov; 7(48):79828-79841. PubMed ID: 27806313 [TBL] [Abstract][Full Text] [Related]
17. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers. Fehl DJ; Ahmed M Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863 [TBL] [Abstract][Full Text] [Related]
18. Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells. Raghunath S; Pudupakam RS; Allen A; Biswas M; Sriranganathan N J Biotechnol; 2017 Oct; 260():91-97. PubMed ID: 28935568 [TBL] [Abstract][Full Text] [Related]
19. Oncolytic virus carrying shRNA targeting SATB1 inhibits prostate cancer growth and metastasis. Mao LJ; Zhang J; Liu N; Fan L; Yang DR; Xue BX; Shan YX; Zheng JN Tumour Biol; 2015 Nov; 36(11):9073-81. PubMed ID: 26084613 [TBL] [Abstract][Full Text] [Related]
20. Virus, Oncolytic Virus and Human Prostate Cancer. Liu GB; Zhao L; Zhang L; Zhao KN Curr Cancer Drug Targets; 2017; 17(6):522-533. PubMed ID: 27993115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]